Trial Profile
SORAFENIB (NEXAVAR) in Combination With Irinotecan in the Second Line Treatment or More of Metastatic Colorectal Cancer With K-RAS Mutation : a Multicentre Two-part Phase I/II Study.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary) ; Sorafenib (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms NEXIRI
- 09 Feb 2012 Actual patient number is 64 according to ClinicalTrials.gov.
- 09 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Jun 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.